Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

La Jolla Pharmaceutical chooses candidate for blood clotting disorder

July 13, 2000

Promising initial results for Synvisc in osteoarthritis of the hip

July 13, 2000

Hydrazine-based inhibitors of TNF-alpha release described by Roche

July 11, 2000

D-Pharm reveals results with prodrug approach to NSAIDs

July 6, 2000

European investigators report immunomodulatory antiarthritic effects for HS-378

July 5, 2000

Compounds with utility for the treatment of cytokine-mediated disorders

July 3, 2000

New iNOS inhibitors claimed by AstraZeneca for use in inflammation and pain

June 30, 2000

E.U. approves Remicade for rheumatoid arthritis

June 30, 2000

Human parvovirus-containing vaccines for rheumatoid arthritis

June 28, 2000

New Pfizer compounds with selectivity for certain MMPs and TACE

June 28, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
Gensci-134: a long-acting growth hormone receptor agonist fusion protein
BioWorld Science
Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone...